Personalis Inc
PSNL8.140USD
-0.270-3.21%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
722.39MMarket Cap
LossP/E TTM
More Details of Personalis Inc Company
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Personalis Inc Info
Ticker SymbolPSNL
Company namePersonalis Inc
IPO dateJun 20, 2019
CEOHall (Christopher M)
Number of employees229
Security typeOrdinary Share
Fiscal year-endJun 20
Address6600 Dumbarton Circle
CityFREMONT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94555
Phone16507521300
Websitehttps://www.personalis.com/
Ticker SymbolPSNL
IPO dateJun 20, 2019
CEOHall (Christopher M)
Company Executives of Personalis Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
--
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Olivia K. Bloom, CPA
Ms. Olivia K. Bloom, CPA
Independent Director
Independent Director
--
--
Mr. A. Blaine Bowman
Mr. A. Blaine Bowman
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Hall
Mr. Christopher M. (Chris) Hall
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
--
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
16.34M
95.00%
Others
860.15K
5.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Merck & Co Inc
15.82%
Tempus AI Inc
14.32%
Lightspeed Venture Partners
9.19%
ARK Investment Management LLC
8.91%
BlackRock Institutional Trust Company, N.A.
4.88%
Other
46.89%
Shareholders
Shareholders
Proportion
Merck & Co Inc
15.82%
Tempus AI Inc
14.32%
Lightspeed Venture Partners
9.19%
ARK Investment Management LLC
8.91%
BlackRock Institutional Trust Company, N.A.
4.88%
Other
46.89%
Shareholder Types
Shareholders
Proportion
Corporation
30.14%
Investment Advisor
27.10%
Investment Advisor/Hedge Fund
13.92%
Venture Capital
9.28%
Private Equity
3.24%
Hedge Fund
1.99%
Research Firm
1.32%
Individual Investor
1.14%
Pension Fund
0.58%
Other
11.29%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
235
47.23M
53.19%
-84.21K
2025Q2
227
69.99M
79.03%
+1.80M
2025Q1
223
76.78M
86.93%
+10.49M
2024Q4
213
73.54M
83.34%
+21.51M
2024Q3
203
51.51M
73.15%
+1.63M
2024Q2
208
30.80M
57.54%
-8.76M
2024Q1
264
31.11M
59.99%
-9.40M
2023Q4
271
31.05M
62.33%
-8.25M
2023Q3
297
34.10M
70.92%
-7.87M
2023Q2
312
35.53M
73.99%
-8.07M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Merck & Co Inc
14.04M
15.84%
--
--
Jun 30, 2025
Tempus AI Inc
12.72M
14.34%
--
--
Sep 11, 2025
Lightspeed Venture Partners
8.16M
9.2%
--
--
Jun 30, 2025
ARK Investment Management LLC
7.11M
8.02%
-80.27K
-1.12%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.80M
4.28%
+2.10M
+123.36%
Jun 30, 2025
The Vanguard Group, Inc.
3.14M
3.54%
+1.85M
+143.07%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
1.26M
1.43%
+1.26M
--
Jun 30, 2025
AIGH Capital Management, LLC.
2.79M
3.14%
-194.57K
-6.53%
Jun 30, 2025
abrdn Inc.
1.76M
1.98%
+54.71K
+3.21%
Jun 30, 2025
Kennedy Capital Management LLC
653.38K
0.74%
+49.09K
+8.12%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
ARK Genomic Revolution ETF
6.89%
Invesco NASDAQ Future Gen 200 ETF
1.06%
Global X Genomics & Biotechnology ETF
0.67%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Vanguard US Momentum Factor ETF
0.05%
Avantis US Small Cap Equity ETF
0.05%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Value ETF
0.03%
View more
ARK Genomic Revolution ETF
Proportion6.89%
Invesco NASDAQ Future Gen 200 ETF
Proportion1.06%
Global X Genomics & Biotechnology ETF
Proportion0.67%
iShares Micro-Cap ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
Vanguard US Momentum Factor ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.04%
iShares Russell 2000 Value ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Personalis Inc?
The top five shareholders of Personalis Inc are:
Merck & Co Inc holds 14.04M shares, accounting for 15.84% of the total shares.
Tempus AI Inc holds 12.72M shares, accounting for 14.34% of the total shares.
Lightspeed Venture Partners holds 8.16M shares, accounting for 9.20% of the total shares.
ARK Investment Management LLC holds 7.11M shares, accounting for 8.02% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.80M shares, accounting for 4.28% of the total shares.
Merck & Co Inc holds 14.04M shares, accounting for 15.84% of the total shares.
Tempus AI Inc holds 12.72M shares, accounting for 14.34% of the total shares.
Lightspeed Venture Partners holds 8.16M shares, accounting for 9.20% of the total shares.
ARK Investment Management LLC holds 7.11M shares, accounting for 8.02% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.80M shares, accounting for 4.28% of the total shares.
What are the top three shareholder types of Personalis Inc?
The top three shareholder types of Personalis Inc are:
Merck & Co Inc
Tempus AI Inc
Lightspeed Venture Partners
Merck & Co Inc
Tempus AI Inc
Lightspeed Venture Partners
How many institutions hold shares of Personalis Inc (PSNL)?
As of 2025Q3, 235 institutions hold shares of Personalis Inc, with a combined market value of approximately 47.23M, accounting for 53.19% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -25.84%.
What is the biggest source of revenue for Personalis Inc?
In FY2025Q2, the -- business generated the highest revenue for Personalis Inc, amounting to -- and accounting for --% of total revenue.
